ライフサイエンスコーパス: casei

1 sus ATCC 7469 (formerly called Lactobacillus casei).

2 o each other and to the FLP of Lactobacillus casei.

3 transcription factor FNR than the FLP of L. casei.

4 icroencapsulated and co-microencapsulated L. casei.

5 showed strong inhibition to S. mutans and L. casei.

6 ns, Enterococcus faecalis, and Lactobacillus casei.

7 ermentation in the presence of Lactobacillus casei.

8 hancers did not constitute an obstacle to L. casei 01 (>10(8)CFU/g) during storage.

9 L. casei 01 addition produced several volatile compounds, s

10 The effect of the Lactobacillus casei 01 and inulin addition on sheep milk ice cream dur

11 ic acid bacteria and probiotic Lactobacillus casei 01 counts and survival under gastrointestinal cond

12 Inulin did not affect L. casei 01 survival after the passage through simulated ga

13 All formulations supported L. casei 01 viability and maintained above the minimum ther

14 Lactobacillus paracasei subsp. paracasei (L. casei 01); QB - with Bifidobacterium animalis subsp. lac

15 L. casei 01, 6logCFU/mL; 10% w/w inulin, L. casei 01, 6logCFU/mL, respectively) were manufactured.

16 eep milk cream; 10% w/w sheep milk cream, L. casei 01, 6logCFU/mL; 10% w/w inulin, L. casei 01, 6logC

17 ional mutagenesis of dltD from Lactobacillus casei 102S.

18 Lactobacillus paracasei subsp. paracasei, L. casei 431 (Chr. Hansen A/S) (hereafter, L. casei 431) on

19 ntaining >/=10(9) colony-forming units of L. casei 431 (n = 553) or placebo (n = 551) for 42 d.

20 There was no effect of L. casei 431 on immune responses to influenza vaccination.

21 Daily consumption of L. casei 431 resulted in no observable effect on the compon

22 . casei 431 (Chr. Hansen A/S) (hereafter, L. casei 431) on immune response to influenza vaccination a

23 us, Lactobacillus acidophilus, Lactobacillus casei, Actinomyces naeslundii genospecies (gsp) 1 and 2,

24 acid/base residue E274 of the Lactobacillus casei alpha1,6-fucosidase, including E274A, E274S, and E

25 and predicted secondary structures of the L. casei and B. subtilis Dcps with that of the E. coli acyl

26 s dihydrofolate reductase from Lactobacillus casei and chicken liver.

27 Melting curves of TSs from L. casei and E. coli are compared to that of TS-A from B. s

28 than LY231514 against TS from Lactobacillus casei and Escherichia coli.

29 dentified as relevant VOCs for Lactobacillus casei and Lactobacillus paracasei subsp.

30 dentified as relevant VOCs for Lactobacillus casei and Lactobacillus paracasei subsp. paracasei.

31 sules was studied in terms of survival of L. casei and release of oil in sequential exposure to simul

32 tobacillus rhamnosus (formerly Lactobacillus casei) and Bacillus subtilis.

33 ndii, Mycobacterium avium, and Lactobacillus casei) and showed good to modest activity against these

34 herichia coli, 35 and 56% with Lactobacillus casei, and 23 and 40% with Thermotoga maritima, respecti

35 carinii, T. gondii, rat liver, Lactobacillus casei, and Escherichia coli, and selected analogues were

36 4 in Escherichia coli, Y146 in Lactobacillus casei, and Y135 in humans) was assumed to serve as the g

37 d and compared NMR solution structures of L. casei apo DHFR and its binary and ternary complexes with

38 which could not be directly detected for L. casei apo DHFR because of line broadening from exchange

39 sured on assigned signals from Lactobacillus casei apo-DHFR and its binary and ternary complexes with

40 and vancomycin, whereas L. rhamnosus and L. casei are resistant to metronidazole and vancomycin.

41 We selected Lactobacillus casei as a model microorganism to proceed to genomewide

42 correlate (R = 0.98) with the Lactobacillus casei assay for whole blood folate.

43 olate values obtained with the Lactobacillus casei assay have formed the basis for current ranges and

44 ncreased miR-192 expression, whereas only L. casei association increased miR-200b and miR-215 express

45 robial viability was found by cultivating L. casei at 31 degrees C and pH 5.8 (optimised conditions).

46 up-regulated during logarithmic growth of L. casei ATCC 334 on sucrose isomers.

47 tion of the genome sequence of Lactobacillus casei ATCC 334 revealed two operons that might dissimila

48 To test this hypothesis, cells of L. casei ATCC 334 were grown in a defined medium supplement

49 id tolerance response (ATR) in Lactobacillus casei ATCC 334.

50 t of the amount of immobilized Lactobacillus casei ATCC 393 on wheat grains on the generation of vola

51 c culture (free or immobilized Lactobacillus casei ATCC 393 on wheat grains) and the ripening time on

52 us acidophilus (ATCC(R) 4356), Lactobacillus casei (ATCC(R) 393) and Lactobacillus paracasei subsp. p

53 llus paracasei CNCM I-3689 and Lactobacillus casei BL23, on L. monocytogenes and orally acquired list

54 hages present in the genome of Lactobacillus casei BL23.

55 acillus plantarum CECT 220 and Lactobacillus casei CECT 475) in order to evaluate the ability of SPC

56 KD that involves injection of Lactobacillus casei cell wall extract (LCWE), we investigated the role

57 After injection of Lactobacillus casei cell-wall extract (LCCWE), mice develop a focal co

58 parison reasons, sausages containing free L. casei cells or no starter culture as well as a similar c

59 by the otherwise strong cytokine inducer L. casei CHCC3139, while IL-10 production remained unaltere

60 e dihydrofolate reductase from Lactobacillus casei complexed with methotrexate, NADPH and 264 crystal

61 was shown to be a suitable substrate for L. casei cultivation and for the development of an alternat

62 L. casei Dcp is 46% identical to the putative product of dl

63 udy is to evaluate the role of Lactobacillus casei DG (LC-DG) and its postbiotic (PB) in modulating t

64 on structure of the complex of Lactobacillus casei dihydrofolate reductase (18.3 kDa, 162 amino acid

65 e X-ray studies of the ternary complex of L. casei dihydrofolate reductase formed with methotrexate a

66 the eight arginine residues in Lactobacillus casei dihydrofolate reductase in its binary complex with

67 ects of heat-killed LAB strain Lactobacillus casei DK128 (DK128) on influenza viruses.

68 t tryptophan 82 mutants of the Lactobacillus casei enzyme produced 5-(2-hydroxyethyl)thiomethyl-dUMP

69 n the crystal structure of the Lactobacillus casei enzyme.

70 lso evaluated as inhibitors of Lactobacillus casei, Escherichia coli, and rat and rh thymidylate synt

71 were evaluated against human, Lactobacillus casei, Escherichia coli, Streptococcus faecium, and Pneu

72 e ternary crystal structure of Lactobacillus casei FPGS.

73 ivo challenge, we identified a core of 47 L. casei genes necessary for its establishment in the gut.

74 , ThiT) were identified in the Lactobacillus casei genome, expressed in Lactococcus lactis, and funct

75 hat provides a representative view of the L. casei genome.

76 g-nu/+ mice were significantly reduced by L. casei GG and B. animalis.

77 philus, Lactobacillus reuteri, Lactobacillus casei GG, and Bifidobacterium animalis) to colonize, inf

78 philus, Lactobacillus reuteri, Lactobacillus casei GG, or Bifidobacterium animalis) in the gastrointe

79 nized with pure cultures of L. reuteri or L. casei GG.

80 st, the N229(177)V mutation in Lactobacillus casei has minimal effect on activity).

81 to the C-terminal fragment of Lactobacillus casei HPrK/P and the C-terminal domain of Staphylococcus

82 ed to B. animalis VKB (1.70 +/- 0.21) and L. casei IMVB-7280 (1.80 +/- 0.20).

83 three probiotic strains (2:1:1 Lactobacillus casei IMVB-7280, Bifidobacterium animalis VKL, Bifidobac

84 obiotics B. animalis VKL, B. animalis VKB, L.casei IMVB-7280, respectively.

85 Using the structure of TS from Lactobacillus casei in complex with the nonsubstrate analogue phenolph

86 ainst Streptococcus mutans and Lactobacillus casei (in both planktonic growth and biofilm formation).

87 In analogous fashion, L. reuteri reduced L. casei-induced up-regulation of B7-2.

88 L. casei IUOM-14 did not degrade any of the substrates.

89 da albicans, Escherichia coli, Lactobacillus casei, L. reuteri, L. acidophilus, a Bifidobacterium sp.

90 Three probiotic strains namely Lactobacillus casei, Lactobacillus brevis and Lactobacillus plantarum

91 featured by decreased level of Lactobacillus casei, Lactobacillus johnsonii and increased E. coli.

92 Lactobacillus casei, Lactobacillus johnsonii, and Lactobacillus delbru

93 being clinically significant: Lactobacillus casei, Lactobacillus rhamnosus, and Lactobacillus leichm

94 ) in their cross-bridge, such as Lactococcus casei, Lactococcus lactis, and Enterococcus faecium.

95 tobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)

96 tobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2) within 1

97 R, Escherichia coli (ec) DHFR, Lactobacillus casei (lc) DHFR and tgDHFR with hDHFR as the mammalian r

98 The analogues 2-4 inhibited Lactobacillus casei (lc) TS and recombinant human (h) TS with IC50 in

99 hs), Escherichia coli (ec) and Lactobacillus casei (lc) were elucidated and compared using intrinsic

100 ell wall extract isolated from Lactobacillus casei (LCCWE) into mice causes a focal coronary arteriti

101 contrast, per 1 unit increase in log(10) L. casei levels, there was a 42 gm increase in birth weight

102 ation with a probiotic strain, Lactobacillus casei LOCK 0900, on selected parameters related to prote

103 tested for antibacterial activity against L. casei, M. tuberculosis H37Ra, and three M. avium strains

104 minerals or a probiotic agent (Lactobacillus casei) may impact recurrence rates.

105 /ml (2.27 nM) [(3)H]folic acid in Folic Acid Casei Medium.

106 ducing a probiotic beverage by Lactobacillus casei NRRL B442.

107 th no effect (p<0.05) of inoculation with L. casei on its level.

108 y 2-3-fold higher than TS from Lactobacillus casei or Escherichia coli.

109 overcomes the barrier that had prevented L. casei random mutagenesis, we developed a signature-tagge

110 D-alanyl-lipoteichoic acid in Lactobacillus casei requires the 56-kDa D-alanine-D-alanyl carrier pro

111 ined by microbiological assay (Lactobacillus casei rhamnosus) and tri-enzyme (protease, alpha-amylase

112 d whether an intervention with Lactobacillus casei Shirota (LcS) in elderly nursing home residents re

113 D: +0.46; 95% CI: 0.08, 0.85) but not for L. casei Shirota (SMD: +0.26; 95% CI: -0.30, 0.82).

114 owel movements/wk) but not for Lactobacillus casei Shirota (WMD: -0.2 bowel movements/wk; 95% CI: -0.

115 ics subsp. lactis strain X and Lactobacillus casei strain B extracts had an MIC of 10mg/ml after 48 h

116 films (Actinomyces naeslundii, Lactobacillus casei, Streptococcus mitis, Veillonella parvula, and Fus

117 h of chloramphenicol-resistant Lactobacillus casei subspecies rhamnosus (NCIMB 10463).

118 provided by experiments that showed that L. casei survival at pH 2.5 was improved at least 100-fold

119 st global functional genomics analysis of L. casei symbiosis.

120 ts agree well with those using Lactobacillus casei, the current gold standard reference assay.

121 ary complexes of the wild-type Lactobacillus casei thymidylate synthase enzyme.

122 ment set of 19 mutants at position 221 of L. casei thymidylate synthase.

123 surface hydrophobicity and the ability of L. casei to adhere to the intestinal wall.

124 n synbiotic ice cream and the adhesion of L. casei to Caco-2 cells was observed.

125 ed after low-dose probiotic or Lactobacillus casei treatment, but B7RP-1 showed increased expression

126 imilar to previously described Lactobacillus casei TS inhibition studies with sulfhydryl reagents, th

127 With three C-terminal mutants of L. casei TS, HETM-dUMP formation was consistent with a mode

128 ement set of mutations at position 146 of L. casei TS.

129 el of KD in which injection of Lactobacillus casei wall extract (LCWE) induces coronary arteritis, we

130 In the bacterial synthesis, Lactobacillus casei was grown in the presence of 1 ng/ml (2.27 nM) [(3

131 ga-3 rich tuna oil and probiotic bacteria L. casei were produced using whey protein isolate-gum Arabi

132 robiotic products (e.g., L. rhamnosus and L. casei) were identical, by 16S rRNA gene sequencing, to o

133 and elicit cytokines and used Lactobacillus casei, which often predominates in deep carious lesions